PANDAA-PED

Treatment of children aged 6-18 with chronic hepatitis C virus using a pan-genotypic direct-acting antiviral drug (sofosbuvir/velpatasvir)

INTERVENTIONAL NON-RANDOMIZED OPEN-LABEL CLINICAL TRIAL

Dear Sir/Madam,

We invite you to participate in a non-commercial clinical trial aimed at determining the effectiveness and safety of the Sofosbuvir/Velpatasvir (SOF/VEL) therapy in pediatric patients with chronic hepatitis C virus.

If you experience any technical problems, please contact:

BioStat Sp. z o.o.
Kowalczyka 17, 44-206 Rybnik
Tel: 666 069 834
Email: [email protected]